EGFR and osteosarcoma: The combination therapy of Na131I-labeled and DOX-loaded PLGA nanoparticles is the first study to research the effects of treating MG-63 osteosarcoma with the co-administration of DOX and Na131I in an anti-EGFR targeted PLGA nanotherapeutic.